Composition
- Active ingredients
- DOLUTEGRAVIR 50MG; LAMIVUDINE 300MG; TENOFOVIR ALAFENAMIDE 25MG
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA215187.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Dolutegravir;Lamivudine;Tenofovir Alafenamide
- Active substance
- dolutegravir
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Lupin Pharms
- Status
- Tentative approval
- FDA approval
- 18 Jul 2023
- Application
- NDA215187-001